Canadian researchers received approval Tuesday from the U.S. Food and Drug Administration to begin testing an experimental and potentially breakthrough HIV vaccine on human subjects with the first phase of clinical trials scheduled for January, the National Post has reported.
Phase 1. Beginning in January 2012, this phase will involve 30 HIV-positive people on whom safety will be retested.Doctors were able to completely eliminate the virus from Timothy Ray Brown by giving him a series bone marrow and stem cell transplants. Unfortunately, that line of treatment is not realistic for treating the 35 million people worldwide currently living with HIV-AIDS because it requires a huge amount of time and resources including multiple compatible transplant donors.
Phase 2. This phase will examine immune responses in humans and will involve 600 HIV-negative people who are at high risk of contracting the AIDS virus.
Phase 3. This phase will determine the efficacy of the vaccine and will involve 6,000 HIV-negative volunteers at high risk of contracting the virus.